Kala Pharmaceuticals (United States)

company in Waltham, United States

KALA Nasdaq SEC CIK 1479419
Follow Kala Pharmaceuticals (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$1.6M +85.8% vs same quarter last year
EPS, diluted -
Operating cash flow −$1.5M +90.7% vs same quarter last year
Operating income −$1.7M +84.4% vs same quarter last year
Net income by quarter
−$9M
−$8.2M
−$8.9M
−$11.2M
−$7.6M
$686K
−$1.6M
−$1.6M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$27M
FY24$0−$38.5M
FY23$0−$42.2M
FY22$3.9M−$44.8M
FY21$11.2M−$142.6M
FY20$6.4M−$104.3M
FY19$6.1M−$94.3M
FY18-−$66.7M
FY17$0−$42.2M
FY16$0−$33.2M
FY15$45K−$16.7M
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22−2099.3%−1151.6%
FY21−1158.8%−1268.7%
FY20−1512.6%−1639.8%
FY19−1452.5%−1553.3%
FY18--
FY17--
FY16--
FY15−35435.6%−37071.1%
FY14--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19−$94.1M
FY18−$55.7M
FY17−$34.6M
FY16−$27.5M
FY15−$15.3M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Kala Pharmaceuticals (United States)
  • Healthcare median
−40000%−30000%−20000%−10000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearKala Pharmaceuticals (United States)Healthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22−1151.6%−80.4%
FY21−1268.7%−71.9%
FY20−1639.8%−62.2%
FY19−1553.3%−46.3%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15−37071.1%−38.4%
FY14-−35.5%